Your browser doesn't support javascript.
loading
Beating tissue factor at its own game: Design and properties of a soluble tissue factor-independent coagulation factor VIIa.
Sorensen, Anders B; Tuneew, Inga; Svensson, L Anders; Persson, Egon; Østergaard, Henrik; Overgaard, Michael Toft; Olsen, Ole H; Gandhi, Prafull S.
Afiliação
  • Sorensen AB; Global Research, Novo Nordisk A/S, DK-2760 Måløv, Denmark; Department of Chemistry and Bioscience, Aalborg University, DK-9220 Aalborg, Denmark. Electronic address: abs@evaxion-biotech.com.
  • Tuneew I; Global Research, Novo Nordisk A/S, DK-2760 Måløv, Denmark.
  • Svensson LA; Global Research, Novo Nordisk A/S, DK-2760 Måløv, Denmark.
  • Persson E; Global Research, Novo Nordisk A/S, DK-2760 Måløv, Denmark.
  • Østergaard H; Global Research, Novo Nordisk A/S, DK-2760 Måløv, Denmark.
  • Overgaard MT; Department of Chemistry and Bioscience, Aalborg University, DK-9220 Aalborg, Denmark.
  • Olsen OH; Global Research, Novo Nordisk A/S, DK-2760 Måløv, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, Section for Metabolic Receptology, University of Copenhagen, Blegdamsvej 3b, DK-2200 Copenhagen N, Denmark.
  • Gandhi PS; Global Research, Novo Nordisk A/S, DK-2760 Måløv, Denmark. Electronic address: pgan@novonordisk.com.
J Biol Chem ; 295(2): 517-528, 2020 01 10.
Article em En | MEDLINE | ID: mdl-31801825
ABSTRACT
Two decades of research have uncovered the mechanism by which the complex of tissue factor (TF) and the plasma serine protease factor VIIa (FVIIa) mediates the initiation of blood coagulation. Membrane-anchored TF directly interacts with substrates and induces allosteric effects in the protease domain of FVIIa. These properties are also recapitulated by the soluble ectodomain of TF (sTF). At least two interdependent allosteric activation pathways originate at the FVIIasTF interface are proposed to enhance FVIIa activity upon sTF binding. Here, we sought to engineer an sTF-independent FVIIa variant by stabilizing both proposed pathways, with one pathway terminating at segment 215-217 in the activation domain and the other pathway terminating at the N terminus insertion site. To stabilize segment 215-217, we replaced the flexible 170 loop of FVIIa with the more rigid 170 loop from trypsin and combined it with an L163V substitution (FVIIa-VYT). The FVIIa-VYT variant exhibited 60-fold higher amidolytic activity than FVIIa, and displayed similar FX activation and antithrombin inhibition kinetics to the FVIIa.sTF complex. The sTF-independent activity of FVIIa-VYT was partly mediated by an increase in the N terminus insertion and, as shown by X-ray crystallography, partly by Tyr-172 inserting into a cavity in the activation domain stabilizing the S1 substrate-binding pocket. The combination with L163V likely drove additional changes in a delicate hydrogen-bonding network that further stabilized S1-S3 sites. In summary, we report the first FVIIa variant that is catalytically independent of sTF and provide evidence supporting the existence of two TF-mediated allosteric activation pathways.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Coagulação Sanguínea / Tromboplastina / Engenharia de Proteínas / Fator VIIa Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Biol Chem Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Coagulação Sanguínea / Tromboplastina / Engenharia de Proteínas / Fator VIIa Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Biol Chem Ano de publicação: 2020 Tipo de documento: Article